GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aadi Bioscience Inc
Aadi Bioscience, a biotech company focused on treating rare cancers, is driven by the commercial success of its lead drug. Its price reflects sales volumes as well as research results to expand its use.
Share prices of companies in the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of cancers with genetic mutations in the mTOR pathway. We classify it in the "Cancer Treatment" sector. The chart below shows the overall dynamics of this targeted area.
Broad Market Index - GURU.Markets
Aadi Bioscience is an oncology company that has developed a drug to treat a rare type of sarcoma. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Aadi shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
WHWK - Daily change in the company's share price Aadi Bioscience Inc
For Aadi Bioscience Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about the commercialization of its drugs and clinical trials, and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Cancer cure
For Aadi Bioscience Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about the commercialization of its drugs and clinical trials, and is an important metric for assessing risk.
Daily change in the price of a broad market stock, index - GURU.Markets
Aadi Bioscience is a biotech company focused on treating rare cancers. Its shares are mired in anticipation of clinical trial results and regulatory decisions. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aadi Bioscience Inc
Aadi Bioscience Inc's year-over-year performance is a story about the commercialization of its drug for the treatment of a rare cancer. Its market capitalization growth over the past 12 months reflects the sales volume of this niche product, but also, more importantly, the results of studies on its use in other tumor types with the TSC mutation, which could significantly expand its market.
Annual dynamics of market capitalization of the market segment - Cancer cure
Aadi Bioscience is a commercial-stage biopharmaceutical company focused on treating rare cancers. Its success depends on the commercialization of its approved drug. The chart shows how its niche strategy and efforts to expand the reach of its drug impact its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
The ticker symbol WHWK belongs to Aadi Bioscience (AADI). Aadi is a biopharmaceutical company whose stock performance is driven by the sales success of its drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects events in the world of biotechnology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Its monthly growth is driven by sales of its drug Fyarro and progress in expanding its indications. Quarterly revenue reports and new clinical trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Aadi Bioscience Inc. is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of cancers with specific genetic mutations. The dynamics of its sector, shown in the graph, reflect trends in personalized oncology. Against this backdrop, one can assess how its targeted drug is progressing in the market for the treatment of rare tumors.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aadi Bioscience is an oncology company whose value is tied to the success of its targeted drug. The chart below shows that the company's monthly stock price fluctuations are not correlated with overall market movements, but rather reflect sales news, new research, and regulatory decisions relevant to its niche product.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aadi Bioscience Inc
Aadi Bioscience, a biopharmaceutical company focused on treating rare cancers, exhibits high volatility. Weekly stock performance depends on drug sales data and new clinical trial results, reflecting the risks and potential of niche oncology.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Aadi Bioscience focuses on treating rare cancers with specific genetic mutations. This highly specialized approach could lead to strong stock movements. The chart will show whether these fluctuations are unique to Aadi or reflect general trends in the targeted oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aadi Bioscience is a biotech company focused on rare cancers. Its shares follow their own rhythm, driven by clinical trial results. The chart shows how independent WHWK's performance is from overall market fluctuations.
Market capitalization of the company, segment and market as a whole
WHWK - Market capitalization of the company Aadi Bioscience Inc
Aadi Bioscience's market capitalization is a financial roadmap for targeted therapy for rare cancers. This company's stock price reflects its confidence in its drug, which targets tumors with specific genetic mutations. Its performance is a barometer of the drug's commercial success and progress in expanding its use to other cancer types.
WHWK - Share of the company's market capitalization Aadi Bioscience Inc within the market segment - Cancer cure
Aadi Bioscience's market share in oncology is focused on treating rare cancers. Its market share is driven by the success of its targeted drug, which targets tumors with specific genetic mutations. This exemplifies how a company can become a leader in a narrow but important niche.
Market capitalization of the market segment - Cancer cure
Aadi Bioscience focuses on treating rare cancers with specific genetic mutations. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the growing trend toward personalized, targeted therapies in oncology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aadi Bioscience is a biopharmaceutical company focused on developing therapies for rare cancers caused by specific genetic mutations. Its market capitalization reflects its niche strategy. The chart below shows the weighting of companies treating orphan cancers.
Book value capitalization of the company, segment and market as a whole
WHWK - Book value capitalization of the company Aadi Bioscience Inc
Aadi Bioscience is a biopharmaceutical company with an approved drug. Its book value is represented by its equity and drug inventory. The chart below shows how the company manages its resources to commercialize its product and fund further research.
WHWK - Share of the company's book capitalization Aadi Bioscience Inc within the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. Its core capital is intellectual property, tied to its drug. Its physical asset allocation will be minimal, reflecting its focus on research rather than large manufacturing facilities.
Market segment balance sheet capitalization - Cancer cure
Aadi Bioscience is a commercial biopharmaceutical company. Its business model is "lightweight," focusing on drug development and commercialization while outsourcing manufacturing. The chart will show whether this structure is typical for the industry as a whole, or whether competitors prefer to own their own factories.
Book value of all companies included in the broad market index - GURU.Markets
Aadi Bioscience's assets are capital focused on commercializing a drug for the treatment of a rare cancer associated with a mutation in the TSC gene. The book value reflects the resources devoted to this niche oncology field, where the company offers the only approved drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aadi Bioscience Inc
Aadi Bioscience is a biotech company focused on treating rare cancers with specific genetic mutations. Its market capitalization is based on its drug, which targets this specific patient group. The chart shows how the market values the commercial potential of this niche oncology drug.
Market to book capitalization ratio in a market segment - Cancer cure
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets rare cancers. Its value is determined by both current sales and the potential for expanded use of the drug. The chart shows how the market evaluates this balance between current revenue and future prospects.
Market to book capitalization ratio for the market as a whole
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. The chart shows how the market values a company with an approved niche drug. Its market capitalization is based on the current and expected sales of the drug, as well as the potential for expansion, creating a high premium for its assets.
Debts of the company, segment and market as a whole
WHWK - Company debts Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. The debt can be used to finance the commercial launch of its drug, as well as to conduct additional clinical trials to expand its indications.
Market segment debts - Cancer cure
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Having an approved drug on the market distinguishes it from many R&D companies. This chart shows the general norms for the pharmaceutical sector, allowing one to assess how Aadi uses revenue from its product to fund further research and commercial expansion.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aadi Bioscience Inc
Aadi Bioscience is focused on developing therapies for rare cancers. Working in such a narrow niche requires significant investment in research with uncertain commercialization prospects. This chart shows the company's debt load, allowing investors to assess the financial risks it faces in bringing its drug to market.
Market segment debt to market segment book capitalization - Cancer cure
Developing targeted therapies for rare cancers, like Aadi Bioscience's, requires precise and expensive research. This chart shows how the biotech sector as a whole finances its activities. It allows us to appreciate how Aadi's financial model, focused on specific genetic mutations, differs from that of large oncology companies.
Debt to book value of all companies in the market
Aadi Bioscience focuses on treating rare cancers with specific genetic mutations. Developing targeted drugs is a long and expensive process. This chart helps assess how the company finances its niche but important mission and how its debt load compares to the broader biotech sector.
P/E of the company, segment and market as a whole
P/E - Aadi Bioscience Inc
This chart shows the valuation of Aadi Bioscience, a biopharmaceutical company focused on treating rare cancers. The valuation reflects how investors view the commercial potential of its currently approved drug and the prospects for expanding its use, which is a key driver of the company's growth.
P/E of the market segment - Cancer cure
This indicator represents the average valuation for the biotech sector in which Aadi Bioscience operates. It reflects the overall level of investor optimism regarding scientific breakthroughs in treating rare cancers. The chart provides a benchmark for understanding how the market assesses Aadi's commercial potential.
P/E of the market as a whole
Aadi Bioscience is a commercial biopharmaceutical company whose drug Fyarro is approved for the treatment of a rare cancer. Its success depends on expanding the use of this drug and commercializing new ones. This chart shows the mood in the biotech sector. It helps understand how the market views the commercial potential of an already approved niche drug and whether it believes in the company's future success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers with specific genetic mutations. The company's future depends on the success of its first drug and the expansion of its use. This graph reflects market expectations regarding the potential of its targeted therapy and its ability to achieve leadership in its oncology niche.
%20P%2FE%20Aadi%20Bioscience%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aadi-Bioscience-Inc&v=1772626558449 "Chart of the company's future (projected) P/E Aadi Bioscience Inc")
Future (projected) P/E of the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on developing therapies for cancers with specific genetic mutations. Its approach is based on precision medicine. This chart reflects expectations for the biotech sector, helping to assess how the market views this highly specialized but potentially highly effective strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772626558469 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Aadi Bioscience is a biopharmaceutical company focused on developing drugs to treat rare cancers with specific genetic mutations. Their business depends on success in clinical trials. This graph of general expectations shows how willing investors are to invest in niche oncology. Market optimism facilitates raising funds to bring drugs to market for small patient groups.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772626558499 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. This graph shows the progression from development to sales. The company's revenue depends on the commercial success of its approved drug, as well as on the results of research to expand its use to treat other oncological diseases.
Profit of companies in the market segment - Cancer cure
Westport Fuel Systems develops systems that enable engines to run on alternative fuels such as natural gas and hydrogen. The company's profitability depends on the speed of the transition to cleaner fuels. This chart illustrates how government regulations and energy prices create growth opportunities, but the cyclical nature of the automotive industry remains a challenge.
Overall market profit
Aadi Bioscience is a commercial biotech company whose drug has been approved for the treatment of a rare cancer. Unlike companies in the development stage, its success now depends on sales volumes and the ability to expand the use of its drug. This demonstrates the shift from scientific uncertainty to operational efficiency in the realities of the marketplace.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company whose drug FYARRO is approved for the treatment of a rare type of cancer. Its revenue forecast depends on the successful launch of this drug and increased sales. This chart reflects analyst expectations regarding FYARRO's commercial potential and the company's ability to effectively market it.
%20profit%20of%20the%20company%20Aadi%20Bioscience%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aadi-Bioscience-Inc&v=1772626558543 "Graph of future (projected) profit of the company Aadi Bioscience Inc")
Future (predicted) profit of companies in the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. Its drug targets tumors with alterations in the TSC1 or TSC2 genes. This chart shows profitability forecasts for the oncology sector. It reflects the trend toward precision medicine, where drugs are tailored to specific patient genetic profiles.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772626558558 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Aadi Bioscience focuses on treating rare cancers with specific genetic mutations. Demand for its drugs is driven by medical needs, not economics. However, this revenue forecast schedule is important because it impacts the overall cost of funding and the strategic decisions of large pharmaceutical companies that may partner with or acquire Aadi.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772626558638 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers with specific genetic mutations. It has one approved drug. The chart shows how investors assess the current and future sales of this niche oncology drug, as well as the potential for expanding its use.
P/S market segment - Cancer cure
Aadi Bioscience Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers with specific genetic mutations. Its lead drug targets tumors with TSC gene alterations. This chart shows the average market valuation for Aadi's niche oncology therapy.
P/S of the market as a whole
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers with genetic mutations. The company already has an approved drug and is conducting further studies. This chart, showing average valuations, helps understand the market premium placed on the revenue of a biotech company working with orphan oncology diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aadi Bioscience Inc
Aadi Bioscience is a biopharmaceutical company focused on treating cancers caused by genetic mutations. This chart reflects investor expectations for sales of its currently approved drug and the expansion of its use. The valuation is based on potential future revenue from targeted therapy for patients with rare tumors.
%20P%2FS%20Aadi%20Bioscience%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aadi-Bioscience-Inc&v=1772626558992 "The graph of the company's future (projected) P/S Aadi Bioscience Inc")
Future (projected) P/S of the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on developing drugs to treat cancers with rare genetic mutations. Its first drug targets tumors with mutations in the TSC1 or TSC2 genes. The chart shows how the market estimates Aadi's future sales, reflecting the potential of its precision oncology developments.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772626559111 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Future revenue forecasts in biotech depend on advances in treating rare cancers. Aadi Bioscience focuses on developing therapies for tumors with specific genetic mutations. Their "one drug, one mutation" approach reflects the trend toward precision oncology and offers hope that effective solutions will be found even for rare diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772626559127 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aadi Bioscience Inc
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. Its revenue is generated by sales of Fyarro, a drug designed to treat a specific type of sarcoma. This chart clearly illustrates the commercial trajectory of a highly targeted oncology drug in a niche but important market.
Sales of companies in the market segment - Cancer cure
Aadi Bioscience is a commercial-stage biopharmaceutical company whose drug Fyarro is designed to treat a rare cancer called PEComa. This chart shows total revenue in the targeted oncology sector. It illustrates the importance and commercial potential of drugs for the treatment of orphan (rare) diseases, for which Aadi Bioscience already has an approved product.
Overall market sales
Aadi Bioscience is a commercial biopharmaceutical company focused on treating cancers with specific genetic mutations. The company already has an approved drug. Its growth depends on successful sales and expanding indications. This overall economic situation impacts healthcare budgets, which determine the availability of expensive cancer drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aadi Bioscience Inc
Aadi Bioscience is a commercial-stage biopharmaceutical company whose drug FYARRO is approved for the treatment of a rare cancer. The company's growth depends on the successful launch of the drug and its expansion. The chart shows analyst revenue expectations, which reflect their sales forecasts for this niche oncology drug.
%20sales%20of%20the%20company%20Aadi%20Bioscience%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aadi-Bioscience-Inc&v=1772626559303 "Schedule of future (projected) sales of the company Aadi Bioscience Inc")
Future (projected) sales of companies in the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company specializing in developing treatments for rare cancers with specific genetic mutations. Its lead drug targets tumors with TSC1/TSC2 gene mutations. This chart displays projected revenues for the entire oncology sector, providing insight into overall expectations for the targeted therapy market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772626559344 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Aadi Bioscience is a commercial biopharmaceutical company focused on treating cancers with specific genetic mutations. Its revenue depends on sales of its approved drug and the success of further research. This overall economic activity affects healthcare budgets, which determine coverage and reimbursement for expensive cancer drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772626559422 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aadi Bioscience Inc
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. This metric reflects its transition from development to sales. It demonstrates how successfully the company converts revenue from its first approved drug into net profit, covering marketing and further research costs.
Market segment marginality - Cancer cure
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets tumors with specific genetic mutations. Profitability depends on successful sales and expansion of indications. This metric reflects the operational efficiency of its commercial model compared to other oncology companies.
Market marginality as a whole
Aadi Bioscience is a commercial biopharmaceutical company whose drug Fyarro is approved for the treatment of a rare cancer. They are also exploring its use in other oncological conditions. This overall profitability curve doesn't affect demand for their drug, which is determined by medical indications, but it may influence investor appetite for their shares.
Employees in the company, segment and market as a whole
Number of employees in the company Aadi Bioscience Inc
Aadi Bioscience is a biopharmaceutical company that has already commercialized a drug for the treatment of a rare cancer. This chart reflects its transition from the research to the commercial stage. Team growth, particularly in sales and medical support, is key to the successful launch and promotion of its niche oncology product.
Share of the company's employees Aadi Bioscience Inc within the market segment - Cancer cure
Aadi Bioscience focuses on developing therapies for cancers with specific genetic mutations. This chart shows the percentage of clinicians and scientists in the field of precision oncology that the company attracts. Its team is working to tailor treatments to a patient's unique tumor profile.
Number of employees in the market segment - Cancer cure
Aadi Bioscience Inc. is a biopharmaceutical company focused on developing therapies for cancers with specific genetic mutations. This chart shows overall employment in the oncology sector. It illustrates the trend toward personalized medicine, where treatment is tailored based on the tumor's genetic profile, which is the foundation of Aadi's approach.
Number of employees in the market as a whole
Aadi Bioscience focuses on developing therapies for rare cancers associated with genetic mutations. The company works in the field of precision oncology, where treatments are tailored to individual patients. This graph illustrates the growing demand for geneticists and bioinformaticians, essential for the development of personalized medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aadi Bioscience Inc (WHWK)
Aadi Bioscience Inc. is a biopharmaceutical company focused on developing therapies for rare cancers. This chart is a prime example of biotech. The astronomically high market capitalization per employee suggests that the market is valuing the potential of a blockbuster drug for a specific patient group, rather than the operational work of a small scientific team.
%20of%20the%20company%20Aadi%20Bioscience%20Inc%20(WHWK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aadi-Bioscience-Inc-WHWK&v=1772626559792 "Chart of market capitalization per employee (in thousands of dollars) of the company Aadi Bioscience Inc (WHWK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Its value is determined by both sales of its existing drug and the potential of new developments. This metric reflects how effectively a small team can commercialize a niche drug and manage research, creating significant market value.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772626559913 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Aadi Bioscience Inc. is a biopharmaceutical company focused on treating rare cancers. It already has one approved drug. The company's valuation per employee reflects both the current sales value of this drug and the potential for expanding its use, which is typical for commercial biotech companies with niche products.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772626559976 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aadi Bioscience Inc (WHWK)
Aadi Bioscience is a biotech company that already has an approved drug (Fyarro) for the treatment of a rare type of cancer. It operates a hybrid model: they spend on R&D for new indications but are already generating revenue. This chart shows the net balance between commercial revenue and R&D expenses per employee.
%20Chart%20Aadi%20Bioscience%20Inc%20(WHWK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aadi-Bioscience-Inc-WHWK&v=1772626560002 "Company Profit Per Employee (in thousands of dollars) Chart Aadi Bioscience Inc (WHWK)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company that already has a commercial product, Fyarro, for the treatment of a rare cancer. This figure is the benchmark they strive to achieve. Their profitability per employee depends on how successfully their sales team can grow drug revenue to exceed R&D and marketing costs.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772626560020 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Aadi Bioscience (WHWK) is a commercial biopharmaceutical company. They already have an approved drug, Fyarro, for the treatment of a rare type of cancer. This chart shows their transition phase. It reflects how sales revenue generated by their commercial team is beginning (or not beginning) to offset high R&D and marketing costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772626560098 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aadi Bioscience Inc (WHWK)
This chart for Aadi Bioscience, a company developing a drug to treat a rare cancer, demonstrates the commercial success of its targeted therapy. The high revenue per employee reflects the high price and value of the niche drug, as well as the effectiveness of its small but focused commercial team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aadi-Bioscience-Inc-WHWK&v=1772626560140 "Sales chart per company employee Aadi Bioscience Inc (WHWK)")
Sales per employee in the market segment - Cancer cure
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations (based on the nab-sirolimus technology). This metric reflects the average revenue per employee by segment. It helps assess how productive Aadi's team is in commercializing its niche oncology drug compared to its competitors.
Sales per employee for the market as a whole
Aadi Bioscience (WHWK) is a biopharmaceutical company focused on treating rare cancers. They already have an approved drug, Fyarro. This metric reflects the drug's commercial success. The increase in revenue per employee demonstrates how effectively their dedicated sales team is promoting this niche drug to oncologists.
Short shares by company, segment and market as a whole
Shares shorted by company Aadi Bioscience Inc (WHWK)
Aadi Bioscience focuses on treating rare cancers using mTOR-related technology. Its only approved drug, Fyarro, has a very narrow market. This chart shows investor bets that the company will be unable to successfully expand its drug to other, larger markets, and that its revenue will remain minimal.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aadi-Bioscience-Inc-WHWK&v=1772626560278 "Short Shares Chart for the Company Aadi Bioscience Inc (WHWK)")
Shares shorted by market segment - Cancer cure
Aadi Bioscience (WHWK) is a biopharmaceutical company focused on treating genetically defined cancers. The company has one approved drug, Fyarro. This chart shows the overall short position in the targeted oncology sector. It reflects market skepticism about the commercial success of this niche drug or the potential of the rest of the pipeline.
Shares shorted by the overall market
Aadi Bioscience (WHWK) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aadi Bioscience Inc (WHWK)
Aadi Bioscience (WHWK) is a biotech with one approved drug (Fyarro) for a rare cancer. Their future depends on the commercial success of this launch. This chart measures how investors view this launch. It shows when the stock is overbought on sales growth expectations or oversold on disappointment.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aadi-Bioscience-Inc-WHWK&v=1772626560391 "RSI 14 indicator chart for the company's stock Aadi Bioscience Inc (WHWK)")
RSI 14 Market Segment - Cancer cure
Aadi Bioscience (WHWK) is a biotech company and a cancer hunter. Their specialty is targeted therapy (based on sirolimus) targeting rare tumors with the mTOR mutation. The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is WHWK's growth due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
Aadi Bioscience (WHWK) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast WHWK (Aadi Bioscience Inc)
Aadi Bioscience is a biopharmaceutical company whose key product, FYARRO, is a targeted therapy (based on nab technology) for the treatment of a rare cancer (PEComa). This chart shows the average analyst price target based on their forecasts for FYARRO's sales and adoption.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-WHWK-Aadi-Bioscience-Inc&v=1772626560483 "A chart showing analyst consensus forecasts for the expected stock price. WHWK (Aadi Bioscience Inc)")
The difference between the consensus estimate and the actual stock price WHWK (Aadi Bioscience Inc)
Aadi Bioscience (WHWK) is a biopharmaceutical company focused on treating rare cancers with mutations in the TSC gene. Their drug, Fyarro, targets this specific population. This chart shows the difference between the current price and the analyst consensus estimate, reflecting their belief in the commercial potential of this ultra-niche oncology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-WHWK-Aadi-Bioscience-Inc&v=1772626560547 "A chart showing the difference between the consensus forecast and the actual stock price. WHWK (Aadi Bioscience Inc)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Aadi Bioscience (WHWK) is a biotech company whose drug Fyarro is approved for the treatment of a rare cancer (PEComa). The company is attempting to expand its use to other tumors. This chart shows overall expectations for the cancer treatment sector, reflecting whether experts believe in the potential of this niche oncology drug.
Analysts' consensus forecast for the overall market share price
Aadi Bioscience is a biopharmaceutical company focused on treating cancer caused by rare mutations (associated with the mTOR protein). This chart shows overall risk appetite. For Aadi, a company with a narrow focus dependent on the success of a single drug, overall market optimism is important for funding, but FDA news and sales volumes carry far more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aadi Bioscience Inc
Aadi Bioscience (WHWK) is a single-product company. Their signature drug is Fyarro, a treatment for a very rare type of cancer (PEComa). Their strategy is a platform drug: they're trying to prove that their technology (based on nab-sirolimus) works in other cancers. This chart represents their R&D bet. It weighs their (tiny) revenue from PEComa against their (big) expansion hopes.
AKIMA Market Segment Index - Cancer cure
Aadi Bioscience (WHWK) is a biopharmaceutical company focused on FYARRO, a drug designed to treat a rare type of cancer (PEComa). This chart shows the average index for the oncology sector. It allows investors to assess how Aadi, with its highly specialized drug, compares to the industry average.
The AKIM Index for the overall market
Aadi Bioscience is a biopharmaceutical company commercializing Fyarro, a drug for the treatment of rare cancers (PEComa). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche oncology company, focused on sales of a single product, compares to overall economic trends.
